-
Zasocitinib Shows Superior Efficacy Over Deucravacitinib in New Phase 3 Trial
NYSE: $TAK A Breakthrough in Psoriasis Treatment New clinical data has emerged that could reshape the treatment landscape for plaque psoriasis. Recent Phase 3 head-to-head study results demonstrate that zasocitinib has achieved superior efficacy compared to deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. Understanding the Clinical Results The study, which directly compared the two…
-
A Breakthrough for Polycythemia Vera: FDA Approves Mimrylo (rusfertide)
NYSE: $TAK A New Chapter in Blood Disorder Management For patients living with Polycythemia Vera (PV), managing hematocrit levels and the risks of blood clots has long been a challenging daily reality. Recently, the medical landscape for this chronic condition saw a significant shift with the FDA approval of Mimrylo (rusfertide). Understanding Mimrylo Mimrylo is…